A vs ILMN
Agilent Technologies and Illumina, Inc., both Healthcare
Agilent Technologies is the larger company at $36B against $25B. On trailing earnings A is the cheaper of the two at a P/E of 32.2 against 42.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +136% against +42% for A. Ryufin's sector-relative Smart Score puts A ahead, 8/10 against 7/10.
| Figure | A | ILMN |
|---|---|---|
| Last close | $160 | $225 |
| Market cap | $36B | $25B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 32.2 | 42.0 |
| Dividend yield | 0.6% | n/a |
| 1-year return | +42% | +136% |
| 5-year return | +8.0% | -53% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Agilent Technologies
Revenue of $1.8B in Q2 2026, net income $339M. Its largest reported line is Life Sciences And Diagnostics Markets, 48% of the disclosed total.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 54% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.